Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists

Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these agents: lack of predictive biomarkers to enable patient se...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinkevitch, Vera, Wappett, Mark, Crawford, Nyree, Price, Stacey, Lees, Andrea, McCann, Christopher, McAllister, Katherine, Prehn, Jochen, Young, Jamie, Bateson, Jess, Gallagher, Lewis, Michaut, Magali, Iyer, Vivek, Chatzipli, Aikaterini, Barthorpe, Syd, Ciznadija, Daniel, Sloma, Ido, Wesa, Amy, Tice, David A., Wessels, Lodewyk, Garnett, Mathew, Longley, Daniel B., McDermott, Ultan, McDade, Simon S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612587/
https://www.ncbi.nlm.nih.gov/pubmed/35086954
http://dx.doi.org/10.1158/1535-7163.MCT-21-0532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612587/
https://www.ncbi.nlm.nih.gov/pubmed/35086954
http://dx.doi.org/10.1158/1535-7163.MCT-21-0532

Ejemplares similares